Exelixis announced that the FDA has extended the review period for its Zanzalintinib New Drug Application due to a major amendment submitted by the company. This pushes the Prescription Drug User Fee Act (PDUFA) action date to March 3, 2027, delaying potential market entry and revenue generation for the drug.
Exelixis submitted updated safety and efficacy data for its Zanzalintinib New Drug Application in response to an FDA information request. The FDA deemed this a 'major amendment,' which automatically triggers a three-month extension of the review period. This delay pushes the PDUFA action date from December 2026 to March 3, 2027. For Exelixis, this means a longer wait for potential market approval and revenue from Zanzalintinib, which could impact investor sentiment and short-term stock performance. While not a rejection, the delay introduces uncertainty and pushes back the timeline for a significant pipeline asset, affecting future earnings projections. Traders should consider the short-term negative pressure on EXEL due to the extended wait for a key drug approval.